Heterocyclic compound
US10106556B2 · kind B2 · utility
7Cited by
0References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 29, 2016 |
| Grant date | Oct 23, 2018 |
| Priority date | — |
| Expiry date | Mar 29, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N9/99
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a compound having an MAGL inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.